Cargando…
What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
The U.S. Food and Drug Administration (FDA) approved inhaled insulin (INH) under the trade name Exubera on January 27, 2006, for use in adult patients with type 1 and type 2 diabetes. Exubera is an inhalable, powdered form of insulin delivered by a device developed by Nektar Therapeutics. Earlier in...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437679/ https://www.ncbi.nlm.nih.gov/pubmed/16515377 http://dx.doi.org/10.18553/jmcp.2006.12.2.169 |